Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer

Jin-Young Park,* Eun Jin Heo,* Jeong-Won Lee, Yoo-Young Lee, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae

Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

ABSTRACT

Objective: Fertility-sparing surgery (FSS) is becoming an important technique in the surgical management of young women with early-stage epithelial ovarian cancer (EOC). We retrospectively evaluated the outcome of laparoscopic FSS in presumed clinically early-stage EOC.

Methods: We retrospectively searched databases of patients who received laparoscopic FSS for EOC between January 1999 and December 2012 at Samsung Medical Center. Women aged ≤40 years were included. The perioperative, oncological, and obstetric outcomes of these patients were evaluated.

Results: A total of 18 patients was evaluated. The median age of the patients was 33.5 years (range, 14 to 40 years). The number of patients with clinically stage IA and IC was 6 (33.3%) and 12 (66.7%), respectively. There were 7 (38.9%), 5 (27.8%), 3 (16.7%), and 3 patients (16.7%) with mucinous, endometrioid, clear cell, and serous tumor types, respectively. Complete surgical staging to preserve the uterus and one ovary with adnexa was performed in 4 patients (22.2%). Two out of them were upstaged to The International Federation of Gynecology and Obstetrics stage IIIA1. During the median follow-up of 47.3 months (range, 11.5 to 195.3 months), there were no perioperative or long term surgical complications. Four women (22.2%) conceived after their respective ovarian cancer treatments. Three (16.7%) of them completed full-term delivery and one is expecting a baby. One patient had disease recurrence. No patient died of the disease.

Conclusion: FSS in young patients with presumed clinically early-stage EOC is a challenging and cautious procedure. Further studies are urgent to determine the safety and feasibility of laparoscopic FSS in young patients with presumed clinically early-stage EOC.

Keywords: Fertility-Sparing Surgery; Laparoscopy; Ovarian Epithelial Cancer

INTRODUCTION

Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy despite recent advances in treatment [1]. Surgical management of EOC consists of complete surgical staging, including hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal washing cytology, multiple biopsies, and pelvic and para-aortic lymph node dissection [2].
Conflict of Interest

No potential conflict of interest relevant to this article was reported.

However, the radicality of extensive surgery can cause irreversible infertility and hormonal deficiency in women younger than 40 years old, who account for 3% to 17% of all EOCs [1,3-7].

In borderline and non-epithelial ovarian tumors, fertility-sparing surgery (FSS), which preserves the uterus and at least one ovary with adnexa is a current recommendation for those under 40 [8-10]. However, the procedure has not yet been examined specifically in women with early-stage EOC, although several retrospective studies have reported postoperative outcomes of FSS in patients with early-stage EOC [11-14]. A recent review article demonstrated that women with grade 1-2, non-clear cell histology, and the International Federation of Gynecology and Obstetrics (FIGO) stage I or with clear cell histology and FIGO stage IA could safely undergo FSS [15]. However, the results of these studies are controversial, stemming from a concern about disease relapse in EOC patients with uterus and adnexa [16].

Despite the concern, fertility sparing is an important issue for young women with early-stage EOC. With the advancement of laparoscopic equipment and surgical skills, several studies reported the feasibility of laparoscopic surgery in gynecologic malignancies, including EOC [17-20]. Furthermore, recent reports of laparoscopic staging surgery for EOC showed both safety and efficacy compared to laparotomy [19,21-24]. The objective of this study was to evaluate the perioperative, oncological, and obstetric outcomes of laparoscopic FSS to determine its feasibility and safety in presumed clinically early-stage EOC.

MATERIALS AND METHODS

We retrospectively reviewed the electronic medical records of patients who had undergone laparoscopic FSS for EOC between January 1999 and December 2012 in the Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea with IRB approval (IRB No.: 2014-05-083-002). Patients aged 40 years or younger were included. Patients who were presumed to have clinically stage I disease and who strongly desired fertility preservation were included. The range of surgical procedures was within the surgeon's discretion, spanning from unilateral salpingo-oophorectomy to complete surgical staging. Complete surgical staging included a complete exploration of the whole peritoneum with multiple biopsies, washing cytology, omentectomy, bilateral pelvic lymph node dissection, and para-aortic lymph node dissection in addition to ovarian tumor removal. The tumor histology of mucinous, serous, endometrioid, and clear cell adenocarcinoma were included. Patients with non-epithelial or borderline ovarian tumors were excluded. Patients who switched to laparotomy procedures were also excluded.

After FSS, patients received adjuvant chemotherapy according to their surgeons’ discretion. During the follow-up period after the primary treatment, patients were scheduled to visit an outpatient clinic every 3 months for the first 2 years, every 6 months for the next 3 years, then once a year as long as there was no evidence of disease recurrence. Patients underwent physical examinations, transvaginal ultrasonography, and serum tumor marker evaluation at every visit to the outpatient clinic. Imaging studies, such as computed tomography (CT), magnetic resonance imaging, and positron emission tomogram (PET) or PET/CT were performed every 6 months to a year.
Perioperative and postoperative long term results including obstetrical and oncological outcomes were evaluated. The rate of recurrence, recurrent interval from the primary treatment, and recurrent site were also reviewed. Data were reported as absolute numbers of patients with percentage or median (range). Statistical analysis was performed using PASW ver. 18 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

1. **Baseline characteristics**
Of 1,044 patients with EOC, we excluded women who were older than 40 years old. Those who did not want to preserve fertility or received primary debulking surgery, neoadjuvant chemotherapy followed by debulking surgery, or palliative surgery followed by chemotherapy were also excluded. Excluding the 28 patients who received open surgery, the remaining 18 patients who underwent laparoscopic FSS were evaluated (Fig. 1).

Baseline characteristics of patients are shown in Table 1. Of the total 18 patients, nine were married. Two patients were presumed to be clinically stage IA before and during the operation. However, they were upstaged to FIGO stage IIIA1 due to the presence of pelvic or para-aortic lymph-node micrometastasis on the final pathologic report. There were no patients with omental or peritoneal metastasis during the operation or at the final pathology. The mucinous type of tumor was the most common (38.9%) histologic type.
Perioperative and long-term outcomes of participants are summarized in Table 2. There were no perioperative complications and no gross residual tumors after the primary surgery. During the median follow-up of 47.3 months (range, 11.5 to 195.3 months), there were no postoperative long-term complications. Patients with high-risk factor, including high grade, clear cell histologic type, tumor growth through capsule, surface excrescences, malignant cells in ascites or peritoneal washings, preoperative rupture, dense adhesion and FIGO stage higher than or equal to IC, received adjuvant chemotherapy. However, two patients who were at clinical stage IA and grade 1 received adjuvant chemotherapy according to the surgeon’s discretion.

Table 1. Baseline characteristics of participants (n=18)

| Characteristic                        | No. (%)          |
|--------------------------------------|------------------|
| Age (yr), median (range)             | 33.5 (14–40)     |
| Nulliparity                          | 14 (77.8)        |
| Previous abdominal operation         | 3 (16.7)         |
| Clinical stage                        |                  |
| IA                                    | 6 (33.3)         |
| IC                                    | 12 (66.7)        |
| Surgical staging                      |                  |
| Complete                              | 4 (22.2)         |
| Comprehensive                         | 14 (77.8)        |
| FIGO stage                            |                  |
| IC1                                   | 2 (11.1)         |
| IIIA1                                 | 2 (11.1)         |
| Incomplete                            | 14 (77.8)        |
| Histology                             |                  |
| Mucinous                              | 7 (38.9)         |
| Endometrioid                          | 5 (27.8)         |
| Clear cell                            | 3 (16.7)         |
| Serous                                | 3 (16.7)         |
| Grade                                 |                  |
| 1                                     | 9 (50.0)         |
| 2                                     | 4 (22.2)         |
| 3                                     | 5 (27.8)         |

FIGO, International Federation of Gynecology and Obstetrics.

Table 2. Perioperative and long-term outcomes of participants (n=18)

| Perioperative and long-term outcomes | Value               |
|--------------------------------------|---------------------|
| Surgical procedure                   |                     |
| Salpingo-oophorectomy                | 18 (100)            |
| Omentectomy                          | 11 (61.1)           |
| Pelvic lymphadenectomy               | 10 (55.6)           |
| Para-aortic lymphadenectomy          | 6 (33.3)            |
| Peritoneal biopsy                    | 4 (22.2)            |
| Peritoneal washing cytology          | 17 (94.4)           |
| Operative time (min)                 | 185 (80–238)        |
| Estimated blood loss (mL)            | 210 (15–520)        |
| Postoperative hemoglobin drop (g/dL) | 1.5 (0.4–5.1)       |
| Postoperative transfusion            | 1 (9.1)             |
| Hospital stay (day)                  | 7 (4–12)            |
| Adjuvant chemotherapy                | 17 (94.4)           |
| Recurrence                           | 1 (5.6)             |
| Death                                | 0                   |
| Pregnancy                            | 4 (22.2)            |

Values are presented as median (range) or number (%).
Although all patients had apparently early-stage disease during initial staging, two were upstaged to FIGO stage IIIA1 due to microscopic metastatic pelvic (n=1) and para-aortic (n=1) lymph nodes after complete staging surgery. The radical surgery including hysterectomy, salpingo-oophorectomy of contralateral ovary, omentectomy, pelvic and para-aortic lymphadenectomy and multiple peritoneal biopsy, was mandatory in this two patients, but they were unmarried with strong desire to preserve their fertility. One of them who had FIGO stage IIIA1 disease because the tumor was involved in the removed ovary with one pelvic lymph node. The histologic type of the tumor was serous adenocarcinoma and the grade was 2. She was treated to 6 cycles of platinum-based combination chemotherapy after primary surgery and was closely monitored during a follow-up period of 41 months. Recently, she was alive with no evidence of disease. Another one who had FIGO stage IIIA1 disease had disease recurrence at 14.9 months after the primary treatment. Preoperative cancer antigen 125 (CA-125) was 21.4 U/mL. No tumor involvement was found except in one ovary in a preoperative imaging study. She received complete staging operation and was upstaged to FIGO stage IIIA1 because the tumor was involved in the removed ovary with one para-aortic lymph node. The histologic type of the tumor was serous adenocarcinoma and the grade was 3. She received 6 cycles of platinum-based combination chemotherapy after the primary surgery. She had no signs or symptoms related to tumor recurrence. However, she had an increased level of tumor marker (CA-125, 73.1 U/mL) with abnormal findings on a follow-up PET/CT. She had multiple recurrent tumors in the left ovary, the hilum of spleen, the surface of the diaphragm and liver,
the serosa of sigmoid colon, multiple tumors in the pelvic and abdominal peritoneum, and multiple tumors in the retroperitoneal lymph nodes. After recurrence, she received debulking surgery, including hysterectomy and salpingo-oophorectomy, followed by platinum-based chemotherapy. The patient’s surgical outcome was successfully achieved as no residual disease state after debulking surgery. Although she received adjuvant chemotherapy after the debulking surgery, she suffered a relapse of the cancer. Currently, she was alive with multiple metastases of the stable disease. All other patients had no disease recurrence. No one died of disease, including the patient who had the recurrence (Table 2).

3. Laparoendoscopic single site surgery for FSS
We demonstrated one case of laparoendoscopic single site (LESS) surgery in Fig. 2. The patient was a 36-year-old nullipara. Her preoperative CA-125 was 42.3 U/mL. Except for the 23 cm sized left ovarian tumor with a solid portion, no other lesion was suspected to be involved in the tumor based on the preoperative abdominopelvic CT scans. Before performing laparoscopic salpingo-oophorectomy, the surgeon aspirated cystic fluid of the tumor through an umbilical incision. The aspirated and sutured cyst was reinserted into the abdominal cavity. The surgical procedure included a left salpingo-oophrectomy, right ovarian wedge biopsy, omentectomy, and exploration of the entire peritoneal cavity. She was presumed to be stage IC1, grade 1, mucinous EOC. She did not receive adjuvant chemotherapy. Disease recurrence was not found during a follow-up period of 39.1 months.

4. Pregnancy outcome after FSS
The clinical characteristics of four women (22.2%) who conceived after primary treatment are shown in Table 3. Two patients received in vitro fertilization and embryo transfer. The other two became pregnant spontaneously after the primary treatment. All patients had received comprehensive surgery and 3 to 6 cycles of adjuvant platinum-based chemotherapy. None of them had disease recurrence (Table 3). The clinicopathologic information of whole study population (n=18) including last disease status and pregnancy outcome, was shown in Table 4.

DISCUSSION
In this study, one out of 18 patients who received laparoscopic FSS for clinically early-stage EOC had disease recurrence. However, no one died of the disease during the median follow-up of 41.3 months. Four out of the 18 patients had successful pregnancies after laparoscopic FSS. There were no perioperative or long term complications after the laparoscopic FSS for clinically early-stage EOC. Up to now, few studies have shown the operative, oncological,
or obstetrical outcomes of laparoscopic FSS for EOC. Although a small number of patients were included in this study, it provides operative, oncologic and pregnancy outcomes of laparoscopic FSS for clinically early-stage EOC.

Selecting appropriate candidates for FSS is a fundamental but complicated problem in treating young EOC patients. The American College of Obstetrics and Gynecology (2007) recommended FSS to reproductive-age EOC patients with grade 1–2 and FIGO stage IA with non-clear cell histology [25]. In 2008, the European Society for Medical Oncology reported that patients with FIGO stage I EOC with grade 1–2 and non-clear cell histology without dense adhesions were optimal candidates for FSS [26]. However, the number of previous reports regarding FSS in EOC patients is limited. In addition, the retrospective design and small sample size of most studies makes it difficult to draw a unanimous consensus for the selection of candidates for FSS.

There are several retrospective studies with relatively larger sample sizes regarding this issue. Schilder et al. [27] reported an excellent survival of conservatively-treated FIGO stage IA or IC EOC patients whose 5-year survival and 10-year survival were 98% and 93%, respectively. Kajiyama et al. [28] reported no difference in 5-year overall survival and disease-free survival between EOC patients who received radical surgery and those who received FSS. They also reported that FIGO stage IC did not affect the prognosis of patients with FSS compared to patients who underwent radical surgery. In this study, the proportion of patients with clinically stage IC EOC was over 60%. None of the patients with stage IC had disease recurrence. However, Satoh et al. [13] suggested that FSS should not be performed in

---

**Table 4. Clinicopathologic information of participants (n=18)**

| Patient no. | Age (yr) | Surgical procedure | Histology | Grade | Clinical stage | 2014 FIGO stage | Adjuvant chemotherapy | Recurrence | Last F/U (mo) | Last status |
|------------|---------|-------------------|-----------|-------|----------------|----------------|----------------------|------------|---------------|-------------|
| 1          | 36      | RSO LORW OMT PLND PALND | Serous    | 3     | IA             | IIIA1          | Yes                  | Yes        | 44            | SD with multiple metastasis |
| 2          | 39      | RSO LOC            | Endometriod | 2     | IA             | Incomplete staging | Yes                  | No         | 30            | NED         |
| 3          | 32      | LSO ROWR RS OMT PLND | Clear cell | 3     | IC1            | Incomplete staging | Yes                  | No         | 34            | NED         |
| 4          | 25      | RSO LORW OMT PLND PALND | Endometriod | 3     | IC1            | IC1            | Yes                  | No         | 61            | NED, 28 wk |
| 5          | 34      | RSO LOC peritoneal multiple biopsy | Clear cell | 3     | IC1            | Incomplete staging | Yes                  | No         | 195           | NED         |
| 6          | 33      | BOC OMT PLND       | Serous    | 2     | IC1            | Incomplete staging | Yes                  | No         | 92            | NED         |
| 7          | 29      | LSO OMT            | Clear cell | 3     | IC2            | Incomplete staging | Yes                  | No         | 66            | NED         |
| 8          | 14      | RSO LOC            | Mucinous  | 2     | IA             | Incomplete staging | Yes                  | No         | 11.5          | NED         |
| 9          | 36      | RSO LORW OMT PLND PALND | Serous    | 2     | IA             | IIIA1          | Yes                  | No         | 41            | NED         |
| 10         | 26      | RSO LOC            | Mucinous  | 1     | IA             | Incomplete staging | Yes                  | No         | 36            | NED         |
| 11         | 34      | RSO LORW PLND PALND | Endometriod | 1     | IC1            | Incomplete staging | Yes                  | No         | 89            | NED         |
| 12         | 15      | RSO LORW OMT PALND | Mucinous  | 1     | IC1            | Incomplete staging | Yes                  | No         | 71            | NED         |
| 13         | 36      | LSO ROWR OMT PLND PALND | Endometriod | 1     | IC1            | IC1            | Yes                  | No         | 68            | NED         |
| 14         | 36      | LESS-LSO ROWR OMT  | Mucinous  | 1     | IC1            | Incomplete staging | No                   | No         | 39            | NED         |
| 15         | 40      | RSO                | Mucinous  | 1     | IA             | Incomplete staging | Yes                  | No         | 44            | NED         |
| 16         | 34      | LSO                | Endometriod | 1     | IC1            | Incomplete staging | Yes                  | No         | 34            | NED         |
| 17         | 27      | RSO LORW OMT PLND  | Mucinous  | 1     | IC1            | Incomplete staging | Yes                  | No         | 49            | NED         |
| 18         | 28      | RSO PLND           | Mucinous  | 1     | IC1            | Incomplete staging | Yes                  | No         | 54            | NED         |

FIGO, International Federation of Gynecology and Obstetrics; F/U, follow-up; LOC, left ovarian cystectomy; LORW, left ovary wedge resection; LSO, left salpingo-oophorectomy; NA, not available; NED, no evidence of disease; OMT, omentectomy; PALND, para-aortic lymph node dissection; PLND, pelvic lymph node dissection; ROC, right ovarian cystectomy; ROWR, right ovary wedge resection; RS, right salpingectomy; RSO, right salpingo-oophorectomy; SD, stable disease.
patients with FIGO stage IC and clear cell histology because they found a 5-year recurrence-free survival of only 66.0%, even though 73.3% patients were treated with platinum-based adjuvant chemotherapy. Many previous reports have suggested that FSS should not be undertaken for EOC patients who have FIGO stage IC and grade 3 due to a high recurrence rate [12,13,27,29]. In this study, one out of three patients with grade 3 had disease recurrence. The tumor involvement was found in the removed ovary and one retroperitoneal lymph node. Even though the patient had 6 cycles of platinum-based adjuvant chemotherapy, she had multiple peritoneal and retroperitoneal recurrences. As shown in this case, grade 3 disease carries a potential risk of micrometastasis with high recurrence, even though preoperative evaluations represent early stage disease.

Because the upstaging rate after a staging operation is nearly 30% in presumed clinically early-stage EOC, complete surgical staging is also important in patients who want to preserve fertility [30,31]. In this study, 10 and 11 patients received pelvic lymphadenectomy and omentectomy, respectively. However, complete surgical staging was done in only four patients (22.2%). Disease recurrence occurred in one patient who received complete surgical staging and was upstaged to FIGO stage IIIA1 with satellite para-aortic lymph node metastasis in final pathology. If she had not received complete surgical staging, she would have been misdiagnosed clinically as stage IA disease. This case suggested that FSS in EOC should be accompanied by complete surgical staging as the first step of treatment.

This study has some limitations other than its low rate of complete surgical staging. Adjuvant chemotherapy was administered even in patients who received comprehensive surgery with clinically stage IA and grade 1 disease. In addition, the grade 1 mucinous type tumor procedure was unnecessary due to the surgeon’s concern of hidden metastasis after performing incomplete surgical staging. Furthermore, the high rate (94.4%) of adjuvant chemotherapy might have influenced the recurrence rate. There was no definite criteria in our institution for selecting appropriate candidates for FSS. Therefore, the decision to perform FSS was largely discretionary, and depended on the surgeon. Because this study was conducted retrospectively, selection bias could not be completely excluded. The small number of study participants and short follow-up period are also limitations of this study. The pregnancy rate in this study is lower (22.2%) compared to previous review articles (50% to 100%) [15,32]. In other articles, the pregnancy rate was calculated among patients who wanted to conceive. However, the number of patient who wanted to conceive was not clearly recorded in the medical records of patients in this study. Despite these limitations, this study has an interesting point because only laparoscopic FSS, including LESS was included. If comparable perioperative, oncologic, and obstetric outcomes are expected, laparoscopic FSS for presumed clinically early-stage EOC can be an alternative procedure to reduce surgical complications associated with laparotomy.

In conclusion, FSS in young patients with presumed clinically early-stage EOC is a challenging and cautious procedure. World-wide indications for selecting optimal candidates for FSS in EOC patients are not established yet. The ethical and practical problems made by a randomized clinical trial of FSS for EOC are difficult. However, laparoscopic FSS with complete surgical staging in young patients with presumed clinically early-stage EOC could be a treatment options in selected patients in accordance with minimally invasive concepts. The accumulation of retrospective studies in the future could determine the safety and feasibility of laparoscopic FSS in young patients with presumed clinically early-stage EOC.
REFERENCES

1. Park B, Park S, Kim TJ, Ma SH, Kim BG, Kim YM, et al. Epidemiological characteristics of ovarian cancer in Korea. J Gynecol Oncol 2010;21:2417.

2. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S161-92.

3. Smedley H, Sikora K. Age as a prognostic factor in epithelial ovarian carcinoma. Br J Obstet Gynaecol 1985;92:839-42.

4. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264-70.

5. Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S, Howell SB. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol 1993;81:651-4.

6. Rodriguez M, Nguyen HN, Averette HE, Steeen AJ, Penalver MA, Harrison T, et al. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer 1994;73:1245-50.

7. Duska LR, Chang YC, Flynn CE, Chen AH, Goodman A, Fuller AF, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999;85:2623-9.

8. Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000;89:391-8.

9. Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17:2670-5.

10. Morice P, Camatte S, El Hassan J, Pautier P, Duvalier P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001;75:92-6.

11. Kawai M, Shibata K, Suzuki S, Ino K, Nawa A, Kawai M, et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol 2010;36:404-8.

12. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol 2008;110:345-53.

13. Sato H, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol 2010;28:1727-32.

14. Kwon YS, Hahn HS, Kim TJ, Kim KT, Lim KT, Lee KH, et al. Fertility preservation in patients with early epithelial ovarian cancer. J Gynecol Oncol 2009;20:44-7.

15. Nam JH, Park JY. Fertility-sparing surgery for young women with early-stage epithelial ovarian cancer. Gynecol Obstet Invest 2013;76:14-24.

16. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v23-30.

17. Chi DS. Laparoscopy in gynecologic malignancies. Oncology (Williston Park) 1999;13:773-82.
18. Gemignani ML, Curtin JP, Zelmanovich J, Patel DA, Venkatraman E, Barakat RR. Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. Gynecol Oncol 1999;73:5-11.

19. Spirtos NM, Eisikop SM, Boike G, Schlaerth JB, Cappellari JO. Laparoscopic staging in patients with incompletely staged cancers of the uterus, ovary, fallopian tube, and primary peritoneum: a Gynecologic Oncology Group (GOG) study. Am J Obstet Gynecol 2005;193:1645-9.

20. Koo YJ, Kim JE, Kim YH, Hahn HS, Lee IH, Kim TJ, et al. Comparison of laparoscopy and laparotomy for the management of early-stage ovarian cancer: surgical and oncological outcomes. J Gynecol Oncol 2014;25:1117.

21. Pomel C, Provencher D, Dauplat J, Gauthier P, Le Boudsocq G, Drouin P, et al. Laparoscopic staging of early ovarian cancer. Gynecol Oncol 1995;58:301-6.

22. Leblanc E, Querleu D, Narducci F, Occelli B, Papageorgiou T, Sonoda Y. Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol 2004;94:624-9.

23. Chi DS, Abu-Rustum NR, Sonoda Y, Ivy J, Rhee E, Moore K, et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 2005;192:1614-9.

24. Tozzi R, Köhler C, Ferrara A, Schneider A. Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol 2004;93:199-203.

25. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007;110:2014.

26. Aebi S, Castiglione M; ESMO Guidelines Working Group. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:i14-6.

27. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:1-7.

28. Kajiyama H, Shibata K, Mizuno M, Nawa A, Mizuno K, Matsuzawa K, et al. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecol Oncol 2011;122:334-8.

29. Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Française d’Oncologie Gynécologique). Hum Reprod 2005;20:1379-85.

30. Schueler JA. Early ovarian carcinoma surgical staging and prognostic factors. Eur J Obstet Gynecol Reprod Biol 1999;85:127-9.

31. Onda T, Yoshikawa H, Yokota H, Yasugi T, Taketani Y. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma: a proposal for essential sites for lymph node biopsy. Cancer 1996;78:803-8.

32. Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani I, et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol 2013;24:138-44.